生殖医学杂志

参考文献

[1]Sanderson PA,Critchley HO,Williams AR,et al.New concepts for an old problem:the diagnosis of endometrial hyperplasia[J].Hum Reprod Update,2017,23:232-254.

[2]Kurman R,Carcangiu M,Herrington C,et al.World Health Organisation classification of tumors of female reproductive organs[M].4th ed.Lyon,France:International Agency for Research on Cancer(IARC)Press,2014.

[3]Kane SE,Hecht JL.Endometrial intraepithelial neoplasia terminology in practice:4-year experience at a single institution[J].Int J Gynecol Pathol,2012,31:160-165.

[4]Committee on Gynecologic Practice,Society of Gynecologic Oncology.The American College of Obstetricians and Gynecologists Committee Opinion no.631.Endometrial intraepithelial neoplasia[J].Obstet Gynecol,2015,125:1272-1278.

[5]Ofinran O,Balega J.The value of magnetic resonance imaging in investigating complex atypical hyperplasia of the endometrium[J].Minerva Ginecol,2016,68:400-404.

[6]Karageyim Karsidag AY,Buyukbayrak EE,Kars B,et al.Transvaginal sonography,sonohysterography,and hysteroscopy for investigation of focal intrauterine lesions in women with recurrent postmenopausal bleeding after dilatation&curettage[J].Arch Gynecol Obstet,2010,281:637-643.

[7]Zinna M,Gentile M,Torcia F,et al.Diagnostic accuracy of sonohysterography vs hysteroscopy in benign uterine endocavitary findings[J].Eur Rev Med Pharmacol Sci,2015,19:365-371.

[8]van Hanegem N,Prins MM,Bongers MY,et al.The accuracy of endometrial sampling in women with postmenopausal bleeding:a systematic review and meta-analysis[J].Eur J Obstet Gynecol Reprod Biol,2016,197:147-155.

[9]Kurman RJ,Kaminski PF,Norris HJ.The behavior of endometrial hyperplasia.A long-term study of“untreated”hyperplasia in 170patients[J].Cancer,1985,56:403-412.

[10]Chandra V,Kim JJ,Benbrook DM,et al.Therapeutic options for management of endometrial hyperplasia[J].J Gynecol Oncol,2016,27:e8.

[11]Trimble CL,Method M,Leitao M,et al.Management of endometrial precancers[J].Obstet Gynecol,2012,120:1160-1175.

[12]Randall TC,Kurman RJ.Progestin treatment of atypical hyperplasia and well-differentiated carcinoma of the endometrium in women under age 40[J].Obstet Gynecol,1997,90:434-440.

[13]Wheeler DT,Bristow RE,Kurman RJ.Histologic alterations in endometrial hyperplasia and well-differentiated carcinoma treated with progestins[J].Am J Surg Pathol,2007,31:988-998.

[14]Ushijima K,Yahata H,Yoshikawa H,et al.Multicenter phase II study of fertility-sparing treatment with medroxyprogesterone acetate for endometrial carcinoma and atypical hyperplasia in young women[J].J Clin Oncol,2007,25:2798-2803.

[15]Gallos ID,Alazzam M,Clark T,et al.RCOG Green-top Guideline:Management of endometrial hyperplasia[EB/OL].2016,Available at://www.rcog.org.uk/globalassets/documents/guidelines/greentop-guidelines/gtg_67_endometrial_hyperplasia.pdf.

[16]Kim MK,Seong SJ,Kim JW,et al.Management of endometrial hyperplasia with a levonorgestrel-releasing intrauterine system:a Korean Gynecologic-Oncology Group study[J].Int J Gynecol Cancer,2016,26:711-715.

[17]Trimble CL,Kauderer J,Zaino R,et al.Concurrent endometrial carcinoma in women with a biopsy diagnosis of atypical endometrial hyperplasia:a Gynecologic Oncology Group study[J].Cancer,2006,106:812-819.

[18]Mutter GL,Kauderer J,Baak JP,et al.Biopsy histomorphometry predicts uterine myoinvasion by endometrial carcinoma:a Gynecologic Oncology Group study[J].Hum Pathol,2008,39:866-874.

[19]Kadirogullari P,Atalay CR,Ozdemir O,et al.Prevalence of co-existing endometrial carcinoma in patients with preoperative diagnosis of endometrial hyperplasia[J].J Clin Diagn Res,2015,9:QC10-QC14.

[20]van der Meer AC,Hanna LS.Development of endometrioid adenocarcinoma despite Levonorgestrel-releasing intrauterine system:a case report with discussion and review of the RCOG/BSGE Guideline on the management of endometrial hyperplasia[J].Clin Obes,2017,7:54-57.

[21]De Marzi P,Bergamini A,Luchini S,et al.Hysteroscopic resection in fertility-sparing surgery for atypical hyperplasia and endometrial cancer:safety and efficacy[J].J Minim Invasive Gynecol,2015,22:1178-1182.

[22]Li X,Feng Y,Lin JF,et al.Endometrial progesterone resistance and PCOS[J].J Biomed Sci,2014,21:2.

[23]Agorastos T,Bontis J,Vakiani A,et al.Treatment of endometrial hyperplasias with gonadotropin-releasing hormone agonists:pathological,clinical,morphometric,and DNA cytometricdata[J].Gynecol Oncol,1997,65:102-114.

[24]Ohyagi-Hara C,Sawada K,Aki I,et al.Efficacies and pregnant outcomes of fertility-sparing treatment with medroxyprogesterone acetate for endometrioid adenocarcinoma and complex atypical hyperplasia:our experience and a review of the literature[J].Arch Gynecol Obstet,2015,291:151-157.